July 15, 2021

NoCamels

SaNOtize, the company behind an antiviral nasal spray for use against COVID-19, has begun selling its product in Israel and Bahrain, officially rolling out the Enovid, the company’s Nitric Oxide Nasal Spray (NONS)

SaNOtize Rolls Out Anti-COVID Nasal Spray In Israel, Bahrain


July 14, 2021

Which.co.uk

The advantage of SaNOtize’s nasal spray over others

“Nasal sprays may yet be a promising weapon against Covid:

Clinical trials of a nasal spray called Sanotize in the UK also look promising for use in people already infected with Covid. The spray, which is not yet available to purchase, could prevent the transmission of Covid, shorten its course and reduce the severity of symptoms in those already infected – according to strong phase two trial results.

Pankaj Sharma, Professor of neurology and director of the Institute of Cardiovascular Research at Royal Holloway, University of London, explains that the spray works by delivering nitric oxide into the nasal cavity, where the virus incubates when it first enters our bodies.

Nitric oxide has been shown to inactivate the Covid virus by disrupting its structural integrity. Our bodies produce nitric oxide naturally and it helps with important bodily functions such as widening the blood vessels to allow for blood flow. “


July 11, 2021

The Jerusalem Post

Enovid, a spray developed in Canada by SaNOtize and manufactured in Israel has been found to reduce viral loads in confirmed COVID-19 cases by 95% in 24 hours and 99% in 72 hours

Made-in-Israel anti-viral nasal spray found effective against COVID


June 30, 2021

Scrip Pharma Intelligence

SaNOtize is to start Phase III trials for its nitric oxide nasal spray for COVID-19 and hopes to enlist volunteers from several countries, including India. The Canadian firm claims initial studies have demonstrated effectiveness across SARS-CoV-2 mutations, with plans afoot to validate it against the spreading Delta variant.

Canadian Biotech Progresses COVID-19 Nasal Spray, Claims Promise Against Variants


March 22, 2021

BNN Bloomberg

SaNOtize CEO Dr. Gilly Regev speaks with BNN Bloomberg about the company’s nitric oxide nasal spray for treatment and prevention of COVID-19.

We want to be a product approved for Canadians: SaNOtize CEO on COVID-fighting nasal spray


March 15, 2021

Nasal Spray found effective against COVID-19 in UK Trial

Major News Outlets

Broadcast


January 18, 2021

CTV News Ottawa

SaNOtize CEO Dr. Gilly Regev speaks with CTV Ottawa about the company’s nitric oxide nasal spray for treatment and prevention of COVID-19.

New Canadian Tool to Fight COVID-19 – Video


January 13, 2021

CalcalistTech

Canadian healthtech company SaNOtize, led by Israeli co-founder and CEO Gilly Regev started its clinical trials in the U.K. for its new anti-Covid-19 nasal spray

“Our nasal spray is like a hand sanitizer for your nose and can block 99.9% of Covid-19 viruses,” says CEO


January 12, 2021

FiercePharma

SaNOtize Research and Development, the Canadian developer of the candidate, began phase 2 trials of the nasal spray in its home market after generating preclinical evidence of efficacy, including a rapid 95% reduction in viral load in rodents.

The clinical development program spread to the U.K. this week, where physicians began enrolling subjects in the first European assessment of the prospect.

COVID-19 nasal spray starts clinical development in the U.K.


January 11, 2021

Global News: Video

Video: A Vancouver-based SaNOtize is making an anti-COVID-19 nasal spray that will soon be tested in a clinical trial in the United Kingdom.

Vancouver-based COVID-19 nasal spray to be tested in UK – Video


Global News

A Vancouver-based company called SaNOtize has created a nasal spray that it says can stop COVID-19 from spreading throughout the body and even prevent someone from getting the virus.

Vancouver company’s anti-COVID-19 nasal spray to start clinical trials in U.K.


Jerusalem Post

A new nasal spray that allegedly kills 99.9% of the novel coronavirus has entered clinical trials that will begin today, according to a press release from the producers, the SaNOtize Research and Development Corporation.

Nasal spray to fight COVID begins clinical trials in UK


Express UK

A GROUND-BREAKING nasal spray proven to kill the coronavirus is being tested on Britons. Fifty patients are the first in the UK to be given the new spray – which destroys 99.9 percent of the virus.

Tests start for coronavirus-busting nasal spray


January 10, 2021

The Times UK

A Canadian nasal spray that has been shown to stop the coronavirus from spreading through the body will begin its first UK clinical trial tomorrow.

‘Natural’ nasal spray could stop virus before it enters the bod


Jewish News

SaNOtize’s Nitric Oxide Nasal Spray, developed by a firm co-founded by Israeli Gilly Regev, is believed to kill up to 99.9% of the coronavirus that causes Covid-19.


JOE UK

In the ongoing fight against coronavirus, health authorities in the UK will this week begin trials of a groundbreaking nasal spray, developed by SaNOtize in Canada.

CORONAVIRUS ‘NASAL SPRAY’ TO BE TRIALLED FOR USE IN THE UK


Bury Times

The first UK clinical trials of a nasal spray proven to kill 99.9% of the coronavirus that causes Covid-19 will start tomorrow.

Coronavirus-busting nasal spray starts UK trials tomorrow


Jewish Chronicle

The Nitric Oxide Nasal Spray, developed by Canadian company SaNOtize, proved 99.9 per cent effective in independent lab tests in the US, at Utah State University’s Antiviral Research Institute. It is currently undergoing Phase II clinical trials throughout Canada.

Israeli’s anti-coronavirus nasal spray ‘99.9 per cent’ effective in lab test


iNews UK

Developed by SaNOtize Research and Development Corp. based in Vancouver, Canada, scientists have found that when produced naturally by the human body, nitric oxide is effective in resisting viral infection. The first UK clinical trials of a nasal spray proven to kill 99.9 per cent of the coronavirus are set to begin on Monday.

Nasal spray that can prevent Covid-19 virus to face clinical trials in the UK